• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    PubMed 

    Google Scholar
     

  • Siegel RL, Miller KD, Fuchs HE, Jemal A: Cancer statistics, 2022. CA: Cancer J Clin. 2022;72(1):7–33.

  • McCormack VA, Boffetta P. Today’s lifestyles, tomorrow’s cancers: trends in lifestyle risk factors for cancer in low- and middle-income countries. Ann Oncol. 2011;22(11):2349–57.

    CAS 
    Article 

    Google Scholar
     

  • Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, Narod SA. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(3):387.

    CAS 
    Article 

    Google Scholar
     

  • Joko-Fru WY, Jedy-Agba E, Korir A, Ogunbiyi O, Dzamalala CP, Chokunonga E, Wabinga H, Manraj S, Finesse A, Somdyala N, et al. The evolving epidemic of breast cancer in sub-Saharan Africa: results from the African Cancer Registry Network. Int J Cancer. 2020;147(8):2131–41.

    CAS 
    Article 

    Google Scholar
     

  • Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027–37.

    Article 

    Google Scholar
     

  • Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75.

    Article 

    Google Scholar
     

  • Provenzano E, Ulaner GA, Chin SF. Molecular classification of breast cancer. PET Clin. 2018;13(3):325–38.

    Article 

    Google Scholar
     

  • Vuong D, Simpson PT, Green B, Cummings MC, Lakhani SR. Molecular classification of breast cancer. Virchows Arch. 2014;465(1):1–14.

    CAS 
    Article 

    Google Scholar
     

  • Wang Q, Xu M, Sun Y, Chen J, Chen C, Qian C, Chen Y, Cao L, Xu Q, Du X, et al. Gene expression profiling for diagnosis of triple-negative breast cancer: a multicenter, retrospective cohort study. Front Oncol. 2019;9:354.

    CAS 
    Article 

    Google Scholar
     

  • Beca F, Santos R, Vieira D, Zeferino L, Dufloth R, Schmitt F. Primary relapse site pattern in women with triple-negative breast cancer. Pathol Res Pract. 2014;210(9):571–5.

    Article 

    Google Scholar
     

  • Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(4):452–78.

    CAS 
    Article 

    Google Scholar
     

  • Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020;18(4):479–89.

    CAS 
    Article 

    Google Scholar
     

  • Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021;70(3):607–17.

    CAS 
    Article 

    Google Scholar
     

  • Heeke AL, Tan AR. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. Cancer Metastasis Rev. 2021;40(2):537–47.

    CAS 
    Article 

    Google Scholar
     

  • Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.

    CAS 
    Article 

    Google Scholar
     

  • Kim SK, Ahn SG, Mun JY, Jeong MS, Chu IS. Genomic signature of the standardized uptake value in 18F-fluorodeoxyglucose positron emission tomography in breast cancer. Cancers. 2020;12(2):497.

    CAS 
    Article 

    Google Scholar
     

  • Colin C, Madden SF, Padraig D, Aherne ST, Helena J, Lorraine OD, Gallagher WM, Hennessy BT, Michael M, John C. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis. 2013;10:2300–8.


    Google Scholar
     

  • Rla B, Algc D, Bk A. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease – ScienceDirect. Pharmacol Ther. 2007;115(2):177–207.

    Article 

    Google Scholar
     

  • Brzozowska M, Caka J: Review: Occurrence and distribution of galanin in the physiological and inflammatory states in the mammalian gastrointestinal tract. Front Immunol. 2020;11:602070.

  • Koller A, Bianchini R, Schlager S, Münz C, Kofler B, Wiesmayr S. The neuropeptide galanin modulates natural killer cell function. Neuropeptides. 2017;64:109–15.

    CAS 
    Article 

    Google Scholar
     

  • Zhang L, Fang P, Chai C, Shao L, Mao H, Qiao D, Kong G, Dong X, Shi M, Zhang Z, et al. Galanin expression is down-regulated in patients with gastric cancer. J Int Med Res. 2019;47(3):1241–9.

    CAS 
    Article 

    Google Scholar
     

  • Nagayoshi K, Ueki T, Tashiro K, Mizuuchi Y, Manabe T, Araki H, Oda Y, Kuhara S, Tanaka M. Galanin plays an important role in cancer invasiveness and is associated with poor prognosis in stage II colorectal cancer. Oncol Rep. 2015;33(2):539–46.

    CAS 
    Article 

    Google Scholar
     

  • Stevenson L, Allen WL, Turkington R, Jithesh PV, Proutski I, Stewart G, Lenz HJ, Van Schaeybroeck S, Longley DB, Johnston PG. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer. Clin Cancer Res. 2012;18(19):5412–26.

    CAS 
    Article 

    Google Scholar
     

  • Kanazawa T, Iwashita T, Kommareddi P, Nair T, Misawa K, Misawa Y, Ueda Y, Tono T, Carey TE. Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors. Oncogene. 2007;26(39):5762–71.

    CAS 
    Article 

    Google Scholar
     

  • Perel Y, Amrein L, Dobremez E, Rivel J, Daniel JY, Landry M. Galanin and galanin receptor expression in neuroblastic tumours: correlation with their differentiation status. Br J Cancer. 2002;86(1):117–22.

    CAS 
    Article 

    Google Scholar
     

  • van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218–32.

    Article 

    Google Scholar
     

  • Oshi M, Asaoka M, Tokumaru Y, Yan L, Matsuyama R, Ishikawa T, Endo I, Takabe K: CD8 T cell score as a prognostic biomarker for triple negative breast cancer. Int J Mol Sci 2020;21(18):6968.

  • Telli ML, Nagata H, Wapnir I, Acharya CR, Zablotsky K, Fox BA, Bifulco CB, Jensen SM, Ballesteros-Merino C, Le MH, et al. Intratumoral plasmid IL12 expands CD8(+) T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy. Clin Cancer Res. 2021;27(9):2481–93.

    CAS 
    Article 

    Google Scholar
     

  • Schmidt M, Bohm D, Von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Can Res. 2008;68(13):5405–13.

    CAS 
    Article 

    Google Scholar
     

  • Vagia E, Mahalingam D, Cristofanilli M: The landscape of targeted therapies in TNBC. Cancers (Basel) 2020;12(4).

  • Song L, Guo X, Zhao F, Wang W, Zhao Z, Jin L, Wu C, Yao J, Ma Z. TTC36 inactivation induce malignant properties via Wnt-β-catenin pathway in gastric carcinoma. J Cancer. 2021;12(9):2598–609.

    CAS 
    Article 

    Google Scholar
     

  • Chai H, Xia L, Zhang L, Yang J, Zhang Z, Qian X, Yang Y, Pan W. An adaptive transfer-learning-based deep Cox neural network for hepatocellular carcinoma prognosis prediction. Front Oncol. 2021;11: 692774.

    Article 

    Google Scholar
     

  • Liu Q, Gao J, Chen X, Chen Y, Chen J, Wang S, Liu J, Liu X, Li J. HBP21: a novel member of TPR motif family, as a potential chaperone of heat shock protein 70 in proliferative vitreoretinopathy (PVR) and breast cancer. Mol Biotechnol. 2008;40(3):231–40.

    CAS 
    Article 

    Google Scholar
     

  • He M, Hu C, Deng J, Ji H, Tian W. Identification of a novel glycolysis-related signature to predict the prognosis of patients with breast cancer. World J Surg Oncol. 2021;19(1):294.

    Article 

    Google Scholar
     

  • Zhou X, Xiao C, Han T, Qiu S, Wang M, Chu J, Sun W, Li L, Lin L. Prognostic biomarkers related to breast cancer recurrence identified based on Logit model analysis. World J Surg Oncol. 2020;18(1):254.

    CAS 
    Article 

    Google Scholar
     

  • Jia R, Weng Y, Li Z, Liang W, Ji Y, Liang Y, Ning P. Bioinformatics analysis identifies IL6ST as a potential tumor suppressor gene for triple-negative breast cancer. Reprod Sci. 2021;28(8):2331–41.

    CAS 
    Article 

    Google Scholar
     

  • Wei LM, Li XY, Wang ZM, Wang YK, Yao G, Fan JH, Wang XS. Identification of hub genes in triple-negative breast cancer by integrated bioinformatics analysis. Gland Surg. 2021;10(2):799–806.

    Article 

    Google Scholar
     

  • Xiao X, Zhang Z, Luo R, Peng R, Sun Y, Wang J, Chen X. Identification of potential oncogenes in triple-negative breast cancer based on bioinformatics analyses. Oncol Lett. 2021;21(5):363.

    CAS 
    Article 

    Google Scholar
     

  • Rights and permissions

    Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

    Disclaimer:

    This article is autogenerated using RSS feeds and has not been created or edited by OA JF.

    Click here for Source link (https://www.biomedcentral.com/)